Quick Answer
Aurinia Pharmaceuticals Inc. reported Research And Development Expense of $32.51 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +56.4% in Research And Development Expense from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $13.84 million | Q2 2020: $11.08 million | Q3 2020: $12.24 million | Q1 2021: $9.83 million | Q2 2021: $10.09 million | Q3 2021: $20.07 million | Q1 2022: $12.62 million | Q2 2022: $11.53 million | Q3 2022: $10.97 million | Q1 2023: $13.16 million | Q2 2023: $12.65 million | Q3 2023: $13.61 million | Q1 2024: $5.55 million | Q2 2024: $4.08 million | Q3 2024: $3.05 million | Q1 2025: $5.74 million | Q2 2025: $7.43 million | Q3 2025: $8.44 million.
- Over the full 8 years of available data (2018 to 2025), Aurinia Pharmaceuticals Inc.'s Research And Development Expense has declined by 21.5%.
- Historical annual values: Fiscal year 2025: $32.51 million | Fiscal year 2024: $20.79 million | Fiscal year 2023: $49.64 million | Fiscal year 2022: $44.99 million | Fiscal year 2021: $51.14 million | Fiscal year 2020: $50.33 million | Fiscal year 2019: $52.87 million | Fiscal year 2018: $41.38 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: